Biomater. Sci., 2024, 12,2007-2018
DOI: 10.1039/D3BM02003G, Review Article
DOI: 10.1039/D3BM02003G, Review Article
Mark-Jefferson Buer Boyetey, Yonghyun Choi, Hee-Young Lee, Jonghoon Choi
Drugs for Alzheimer's disease (AD) fail to exhibit efficacy in clinical trials for a number of reasons, a major one being blood–brain barrier (BBB) permeability.
The content of this RSS Feed (c) The Royal Society of Chemistry
Drugs for Alzheimer's disease (AD) fail to exhibit efficacy in clinical trials for a number of reasons, a major one being blood–brain barrier (BBB) permeability.
The content of this RSS Feed (c) The Royal Society of Chemistry